Vanguard Portfolio Management
ABUS icon

Vanguard Portfolio Management’s Arbutus Biopharma ABUS Stock Holding History

Vanguard Portfolio Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.4M Buy
1,541,458
+149,434
+11% +$656K ﹤0.01% 2296
2026
Q1 		$6.26M Buy
+1,392,024
New +$6.09M ﹤0.01% 2258

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's ABUS Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Arbutus Biopharma (ABUS) stake by 11% in Q2 2026, buying an estimated $656K and bringing the position to 1,541,458 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

Vanguard Portfolio Management first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Vanguard Portfolio Management held 1,541,458 shares of Arbutus Biopharma worth $7.4M as of Q2 2026.
  • Vanguard Portfolio Management bought 149,434 Arbutus Biopharma shares in Q2 2026, an estimated $656K.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2296 holding.
  • Vanguard Portfolio Management first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.